IQVIA exceeded analyst expectations for the third quarter of 2026, delivering record revenue and adjusted earnings driven by robust clinical research demand and organic growth acceleration. Following these results, the company raised its full-year 2026 guidance for revenue, Adjusted EBITDA, and Adjusted EPS.
Key Highlights
- Revenue reached $4.43 billion, an 8.0% increase year-over-year and slightly above the $4.37 billion consensus estimate.
- R&D Solutions segment net new bookings were $3.2 billion, up 15% year-over-year, yielding a book-to-bill ratio of 1.2x and a contracted backlog of $32.6 billion.
- Adjusted diluted earnings per share rose 11.3% to $3.34, significantly outperforming the $2.94 analyst forecast.